Alexander M M Eggermont
Alexander M M Eggermont is an expert in Oncology at Institut Gustave Roussy (France). As of June 2026, ScienceLeadR ranks Alexander M M Eggermont in the top 1% of experts worldwide for Skin Neoplasms, Melanoma and Sarcoma. Alexander M M Eggermont has authored 902 publications, the most recent in 2026, and is an investigator in 14 clinical trials, 1 of them ongoing. SLR score: 3,238 (community average: 125). How the SLR is computed.
LeadR Profile
Oncology
Subspecialties: Surgery - Immunology - Hematology
Main Topics
Publications and Clinical Studies
Profile data updated on
Short Biography
Prof. Alexander Maximiliaan Marie EGGERMONT, MD, PhD
- Board of the Comprehensive Cancer Center Munich (CCCM), Technical University Munich & Ludwig Maximilians University, Munich, Germany
- Prof Clinical &Translational Immunotherapy, University Medical Center Utrecht, Netherlands - Senior Investigator and past Chief Scientific Officer Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands
- Coordinator Comprehensive Cancer Center Program Deutsche KrebsHilfe, Germany & Strategic Advisor @ DKFZ-NCT Heidelberg for National Center for Tumors Program, Germany
Past Director General, Gustave Roussy Cancer Campus Grand Paris, France (2010-2019) & Emeritus Professor Oncology, University Paris-Saclay, France (2012-2021)
Emeritus Professor International Networking Cancer Research, ErasmusMC, Rotterdam, NL Emeritus Professor Surgical Oncology Erasmus University Rotterdam, NLHonorary Professor Surgical Oncology, Catholic University Leuven, Belgium,
Fellow of USA NIH-NCI Surgery Branch (Steve Rosenberg) (85-86) PhD1987 TumorImmunology
International (current & past) scientific societal positions
- President European Academy of Cancer Sciences (2010-2019), Executive board (2019-now)
- President Cancer Core Europe 2014-2019
- ECCO President European CanCer Organization 2009-2011
- EORTC President 2006-2009, Exec Board 1998-2012, Chairman Melanoma Group(1994-2000)
- ASCO: Board of Directors of ASCO (2008-2010; Surgery Chair) and JCO Editorial Board
- AACR: Deputy Editor of Clinical Cancer Research 2001-2009
- ESMO: Executive Board: 2014-2018
- CRUK: Board of Trustees/Strategic Research Committee 2016-2019
- DFG: Wissenschaftsrat, Germany: 2017-2020
- DKH (Deutsche Krebshilfe) (Since 2007-Now) President International Jury CCC-Program
- European Journal of Cancer: Editor-in-Chief since 01-01-2011
Professional awards (selection): Joseph Maisin Chair (Catholic University of Louvain, Belgium (2001); ASCO Statesman Award (2010); Michiel Van Vloten Award of the Dutch Surgical Society (2016); John Wayne Award of Clinical Research of Society Surgical Oncology (2018); Doctorate Honoris Causa (University Essen, Germany) (2018); Honorary Chair KAZIOR (Kazakh Cancer Institute)(2019); Deutsche Krebshilfe Cancer Award (2019); European Academy of Tumor Immunology Award (2023), ESSO Award (2023)
Specialties & Scientific Output: Clinical: immunotherapy, melanoma, sarcoma,drug development. Basic/Translational: tumor immunology, animal models. Scientific Output: >1200 publications; 40 PhD theses @ ErasmusMC: H-index/citations: 127, >81000 citations (Web of Science), HI:128, >82000 (Scopus); HI:137, >97000 (Research Gate); HI:148, >115000 citations (Google Scholar)
Societal Awards: Légion d’Honneur, France (2015)
Organizations
Career arc: 1987 - 2026
Number : 902
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment - update 2026. PMID 42263355 — radiotherapy, cells, carcinoma, squamous cell, neoplasms, therapeutics, cutaneous squamous cell carcinoma | Eur J Cancer | 2026 | 0 |
| European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention - Update 2026. PMID 42248744 — cells, carcinoma, squamous cell, neoplasms, neoplasm metastasis, risk factors, cutaneous squamous cell carcinoma | Eur J Cancer | 2026 | 0 |
| On the survival benefit from sentinel node biopsy for melanoma. PMID 42225107 — melanoma, neoplasms, biopsy | Lancet Oncol Top journal | 2026 | 0 |
| Safety and efficacy of intratumoural anti-CTLA4 with intravenous anti-PD1. PMID 42056527 — cells, safety, macrophages, neoplasms, drug-related side effects and adverse reactions, therapeutics, ipilimumab, wounds and injuries | Nature Top journal | 2026 | 0 |
| IO102-IO103 immune-modulatory cancer vaccine and pembrolizumab in melanoma. PMID 42025759 — cells, vaccines, progression-free survival, melanoma, neoplasms, drug-related side effects and adverse reactions, cancer vaccines | Ann Oncol Top journal | 2026 | 0 |
Clinical Studies 14
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Ongoing Clinical Trials
Ongoing trial started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Adjuvant Encorafenib and Binimetinib in High risk Stage II Melanoma With a BRAF Mutation NCT05270044 — melanoma, placebos, tablets, capsules, mutation | Phase 3 | Active not recruiting | 2022 |
LeadR Networks
Main global connection map